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Cyclooxygenase-2 (COX-2) is an inducible form of the enzyme that catalyses the synthesis of prostanoids, including prostaglandin
E2 (PGE
2
), a major mediator of inflammation and angiogenesis. COX-2 is overexpressed in cancer cells and is associated
with progressive tumour growth, as well as resistance of cancer cells to conventional chemotherapy and radiotherapy. These
therapies are often delivered in multiple doses, which are spaced out to allow the recovery of normal tissues between treatments.
However, surviving cancer cells also proliferate during treatment intervals, leading to repopulation of the tumour and limiting the
effectiveness of the treatment. Tumour cell repopulation is amajor cause of treatment failure.The central dogma is that conventional
chemotherapy and radiotherapy selects resistant cancer cells that are able to reinitiate tumour growth. However, there is compelling
evidence of an active proliferative response, driven by increasedCOX-2 expression and downstream PGE
2
release,which contribute
to the repopulation of tumours and poor patient outcome. In this review, we will examine the evidence for a role of COX-2 in cancer
stem cell biology and as a mediator of tumour repopulation that can be molecularly targeted to overcome resistance to therapy.
1. Introduction
To date, intensive cancer research has culminated in an
increased knowledge of primary tumour formation, the
development of sophisticated therapies, and prolonged sur-
vival time of cancer patients. However, cancer remains a
common and lethal disease worldwide with tumour repopu-
lation andmetastasis asmajor causes of cancer-related deaths.
A definitive cure for cancer patients will rely upon further
molecular dissection and targeting of these two processes. In
this regard, there is growing evidence that cancer is a stem
cell disease, where tumours are composed of a mixture of
genetically and functionally distinctive cells that contribute
to tumour outgrowth, and a small population of cancer
stem cells (CSCs) that can drive tumour initiation, therapy
resistance, tumour repopulation, and metastasis. The CSC
model posits that tumours are organised hierarchically in
a similar, albeit distorted, manner as normal tissues. In a
normal tissue, stem cells, at the apex of this hierarchy, give
rise to transit amplifying cells, which proliferate rapidly and
finally enter a postmitotic, differentiated state, in which the
cells fulfill the various functions of the specific organ. CSCs
share important properties with normal stem cells, including
self-renewal and multilineage differentiation potential, and
drive tumour progression as they have the exclusive ability
to perpetuate indefinitely the growth of the tumour and give
rise to a diverse array of differentiated progeny that make-up
the bulk of the tumour mass [1–5]. Seminal work by Bonnet
and Dick in 1997 first identified CSCs in acute myeloid
leukemia [6], and subsequently CSCs have been isolated from
a majority of solid malignancies including breast [5, 7–9],
brain [10], colon [11], osteosarcoma [12, 13], squamous cell
carcinoma [14, 15], and prostate [16, 17]. Most of these studies
have defined CSCs functionally by their elevated tumour-
initiating ability when inoculated into immune-deficient
mice, relative to that of non-CSC cancer cells. Similarly to
normal stem cells, CSCs are highly resistant to the cytotoxic
effects of chemotherapy and radiotherapy and are able to
reinitiate tumour growth [8, 9, 18]. This is seen clinically
where these therapies do shrink the bulk of the tumour, but
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after a remission period of variable length, most patients do
relapse with frequent development of drug resistance and
metastatic dissemination.
Tumours are not only clonal outgrowths of deregu-
lated cancer cells but potentiate their own progression
and survival by fostering a complex and highly dynamic
microenvironment, consisting of the extracellular matrix,
endothelial cells, immune cells, and a plethora of cytokines
and growth factors [19, 20]. Importantly, inflammatory cells
and the cellular mediators of inflammation are prominent
constituents of the microenvironment of all tumours [21].
In some cancers, the inflammatory conditions precede the
development of malignancy, for example, inflammatory
bowel disease is associated with colon cancer. Alternatively,
an oncogenic change can drive tumour-promoting inflam-
mation in tumours that are epidemiologically unrelated to
overt inflammatory conditions [22, 23]. This “smoldering”
inflammation in the microenvironment has many tumour-
promoting effects including tissue remodelling, angiogen-
esis, cancer cell survival, metastasis, and immune evasion
[21, 24]. One key inflammatory mediator deregulated in
many cancers is cyclooxygenase-2 (COX-2). Elevated COX-
2 expression, and that of its principle metabolic product
prostaglandin E2 (PGE
2
), has been shown to be inversely
associated with patient survival [25–27]. Epidemiological,
clinical, and preclinical studies have shown that the inhibition
of PGE
2
synthesis through the use of either nonsteroidal anti-
inflammatory drugs (NSAIDs) or specific COX-2 inhibitors
has the potential to reduce the risk of developing certain
cancers, including breast, head and neck squamous cell
carcinoma, osteosarcoma, pancreas, and prostate cancers,
and to reduce the mortality caused by these cancers [28–
35]. Recently, PGE
2
has been linked to the “phoenix rising
pathway,” in which tissue damage initiates tissue repair [36].
In the context of common cancer therapies, which employ
DNA damaging agents to trigger apoptosis, there is evidence
that apoptotic cells release PGE
2
, a potent growth factor, that
can stimulate the proliferation of surviving CSCs, leading to
accelerated tumour repopulation and patient relapse [37, 38].
In this review, we will focus on the role of COX-2 in cancer
stem cell biology, and as a mediator of tumour repopulation,
and ultimately resistance to therapy.
2. COX-2 Plays a Central Role in Cancer
Cyclooxygenases are enzymes necessary for the metabolic
conversion of arachidonic acid to prostaglandins, including
PGE
2
, a major mediator of inflammation and angiogenesis
(Figure 1). PGE
2
signals through four pharmacologically
distinct G-protein coupled receptors, EP
1
, EP
2
, EP
3
, and
EP
4
, which each activate different downstream signalling
pathways. In turn, PGE
2
is catabolized to the inactive 15-
keto-PGE
2
by the enzyme 15-hydroxyprostaglandin dehy-
drogenase [40, 41]. There are two isoforms of cyclooxyge-
nase: COX-1 and COX-2. Both exist as integral, membrane-
bound proteins, located primarily on the luminal side of
the endoplasmic reticulum and nuclear envelope [42]. COX-
1 is characterised as a housekeeping enzyme required for
the maintenance of basal level prostaglandins [43] and is
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Figure 1: Prostaglandin E2 biosynthesis and downstream cellular
effects. Arachidonic acid is released from cellular membranes and
converted to PGH
2
through the activity of the COX enzymes. COX-
1 is constitutively expressed in many cells, generating low levels of
prostaglandins that are cytoprotective and maintain homeostasis.
In contrast, COX-2 is absent from most cells and is induced
by a number of inflammatory stimuli. PGH
2
is rapidly converted
to PGE
2
, which plays a predominant role in cancer progression
by stimulating tumour cell proliferation, migration, angiogenesis,
apoptosis resistance, invasion, and metastasis. NSAIDS and COX-
IBS can pharmacologically block the activity of the COX enzymes.
expressed constitutively in most tissues. It is responsible for
the maintenance of internal homeostasis by participating
in processes such as platelet aggregation, cytoprotection of
the gastric mucosa, vascular smooth muscle functioning,
and renal function. By contrast, COX-2 usually remains
undetected in healthy tissues and organs. In adults, it is found
only in the central nervous system, kidneys, vesicles, and
placenta, whereas in the fetus, it occurs in the heart, kidneys,
lungs, and skin [40, 44]. COX-2 is highly inducible and can be
rapidly upregulated in response to various proinflammatory
agents, including cytokines, mitogens, and tumour promot-
ers, especially in cells involved in inflammation, pain, fever,
Alzheimer’s disease, osteoarthritis, or tumour formation [42,
45]. Under normal conditions, acute inflammation is a tightly
controlled self-limiting response, where upon abatement
of the inflammatory stimulus, specific cytokines, includ-
ing interleukin-1 (IL-1) and IL-6, exert feedback inhibition
causing COX-2 expression and PGE
2
production to cease
and the inflammatory response to subside. However, with
sustained exposure to proinflammatory stimuli, continued
expression of COX-2 leads to the transition from acute to
chronic inflammation [42, 46]. In recent decades, COX-2
overexpression has been reported in several human cancers
including breast [47–49], lung [47, 50], skin [51], colon
[47, 52, 53], bone [32, 54, 55], cervical [56], oesophageal
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[57], pancreatic [58], prostate [59], and bladder cancer [60].
Constitutive expression of COX-2 and sustained biogenesis
of PGE
2
appear to play predominant roles in the initiation
and promotion of cancer progression. PGE
2
can mediate
these effects through numerous signalling pathways includ-
ing activation of vascular endothelial growth factor (VEGF)
leading to increased cell proliferation, metastatic and invasive
potential, and angiogenesis [61]; increased expression of the
protooncogenes, BCL-2, and the epidermal growth factor
receptor (EGFR), through the activation of the mitogen-
activated protein kinase (MAPK) and the phosphoinosi-
tide 3-kinase (PI3K)/AKT pathway, respectively [62, 63];
increased transcriptional activity of the antiapoptotic medi-
ator nuclear factor 𝜅B (NF𝜅B) [64]; enhanced metastasis and
invasion by activation of matrix metalloproteases (MMP-2
andMMP-9) [65]; and suppression of the production of IL-12,
leading to immunosuppression [66].
Within the context of stem cell biology, PGE
2
has
been heralded as an evolutionarily conserved regulator
of haematopoietic stem cells (HSCs) [67]. Stem cells are
characterised by their unique abilities to both self-renew and
differentiate to produce all mature cell lineages of a given
tissue type [2]. In the adult vertebrate, HSCs reside in the
bone marrow and are crucial to maintain lifelong production
of all blood cells [68]. Utilising zebrafish and mouse models,
the COX-2/PGE
2
axis has been shown to be required for
HSC formation [69], proliferation [70, 71], maintenance of
the haematopoietic lineage [72], and bone marrow recovery
following irradiation injury [69, 73]. Molecular dissection
of the mechanisms by which PGE
2
exerts these effects on
HSCs has identified in vivo evidence that PGE
2
enhances the
activation of Wnt, a key regulator of stem cell self-renewal,
during embryogenesis by stabilising 𝛽-catenin, and thatWnt-
mediated regulation ofHSCdevelopment is PGE
2
-dependent
[67]. Given the stem-cell-enhancing activity of PGE
2
, and
that PGE
2
activates general cell survival and proliferation
pathways, it is unsurprising that upregulation of COX-2 is
associated with populations of CSCs isolated from several
cancer types, including breast [74–77], colon [78, 79], and
bone cancer [13, 80]. COX-2 is coexpressedwithCSCmarkers
including CD44, CD133, Oct3/4, LGR5, SOX-2, and ALDH
[75, 78, 81–84]. A functional marker of CSCs is the ability
to grow as spheroid colonies in defined serum-free culture
conditions that supports the proliferation of undifferentiated
cells [85]. Cells that overexpress COX-2 exhibit greater
sphere forming efficiency and clonogenicity than those
that express low levels of COX-2 [75, 86, 87]. In breast
CSCs, isolated from the primary tumours of HER2/Neu
transgenic mice, COX-2 expression was upregulated 30-fold
in CSCs compared to non-CSCs, and constituted part of
an eight-gene signature that correlated with breast cancer
patient survival [88]. Furthermore, transfection of COX-2
into the ER-positive breast cancer cell line, MCF7, increased
the ability of MCF7 cells to grow as spheres [86]. In our
own work, we have shown that COX-2 expression is elevated
141-fold in the CSC population compared to the non-CSC
population of canine osteosarcoma cells, and that COX-2
inhibition induced a dose-dependent decrease in sphere
forming ability, indicating that COX-2 plays a major role
in tumour initiation [13]. Our data is consistent with a
previous study in which mouse embryonic stem cells
lacking functional COX-2 have a normal growth rate and
differentiation potential but are profoundly compromised
in their ability to form teratocarcinomas in vivo [89].
Furthermore, CSCs isolated from human glioma cell lines,
express constitutively high levels of COX-2 protein that
correlates positively with radioresistance. Inhibition of COX-
2 enhanced radiosensitivity of glioma CSCs and suppressed
the expression of angiogenic and stemness-related genes
[90]. Together, this data suggests that inhibiting COX-2 in
CSCs reduces stem cell characteristics and that COX-2 plays
a vital role in the maintenance and function of the CSC
population.
3. Mechanisms of Resistance to Therapy
The death of all cancer cells in a tumour is the ultimate
goal of cancer therapy. After surgery, radiotherapy and
chemotherapy remain the most important treatment modal-
ities of advanced carcinomas, and although they effectively
shrink the tumour mass, some patients become progressively
unresponsive and ultimately drug resistant [91]. Resistance
can be divided into two broad groups: intrinsic or acquired.
Intrinsic resistance indicates that, prior to receiving the
therapy, resistance-mediating factors preexist in a subset
of cancer cells that make the therapy ineffective, including
increased drug efflux and aberrant DNA damage repair
pathways. Acquired resistance can develop during treat-
ment of tumours that were initially sensitive and can be
caused by mutations arising during treatment, as well as
through other adaptive responses, including activation of
alternative compensatory signalling pathways and evasion of
cell death [92]. Moreover, tumours contain a high degree
of molecular heterogeneity; thus, drug resistance can arise
through therapy-induced selection of a resistant population
of cells that was present in the original tumour [2]. Recent
studies have shown that the extensive heterogeneity observed
within tumours occurs through mechanisms independent
of CSC differentiation and supports a model whereby the
CSC phenotype is dynamic rather than a fixed state. For
example, induction of epithelial-to-mesenchymal transition
(EMT), by ectopic expression of the transcription factors
Twist or Snail, in mammary cancer cells is associated with
CSC qualities and an increased propensity to form tumours
[93, 94]. Similarly, melanoma cells can reversibly turn on
and off the histone demethylase JARID1B, and cells that
express JARID1B are more tumourigenic than those that do
not [95]. And exposure of glioma cells to perivascular nitric
oxide reversibly promotes their ability to form tumours [96].
These findings challenge the unidirectional hierarchical CSC
model: signifying that non-CSCs can dedifferentiate and can
acquire CSC-like properties under certain conditions.
Common cancer therapies produce toxic substances that
destroy crucial cellular macromolecules, including DNA,
leading to cell death. An unfortunate side effect is high
toxicity to normal tissues: to avoid severe toxic reactions,
radiotherapy and chemotherapy are often given in multiple
doses, which are spaced out to allow the repopulation
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of surviving cells in normal tissues during the prolonged
overall treatment time. However, surviving cancer cells also
proliferate during the intervals between treatments and this
process of repopulation is an important cause of treatment
failure [97]. Furthermore, a long recognised phenomenon
is that of accelerated repopulation, where the few surviving
cancer cells that have escaped death after exposure to radio-
therapy or chemotherapy can rapidly repopulate the badly
damaged tumour by proliferating at a markedly accelerated
rate. Subsequent tumour repopulation with resistant cancer
cells often results in amore aggressive cancer phenotype with
poor prognosis for the patient. There is ambiguity regarding
tumour type and repopulation potential: some studies report
that accelerated repopulation occurs only in the late stages of
radiation treatment, whereas other studies, such as those in
cervical cancer [98], squamous cell carcinomas [99], bladder
cancer [100], and colorectal carcinomas [101], show that the
onset time of accelerated repopulation is relatively short [102,
103]. This has implications for treatment regimes, and the
efficacy of therapy. The molecular mechanisms underlying
this process of accelerated tumour repopulation are not well
understood. A seminal study has shown that CSCs, isolated
from bladder urothelial carcinomas, actively proliferate in
response to chemotherapy-induced damages and repopulate
residual tumours between chemotherapy cycles, in a similar
fashion to how normal tissue stem cells mobilise to the site of
a wound during tissue repair [37].
Wound healing and tissue regeneration are essential
processes for all multicellular organisms. Some organisms
have the ability to entirely regenerate amputated limbs, such
as salamanders [104], whereas other organisms can only
partially replace damaged organs, such as humans [105]. The
resident tissue stem cells play a crucial role in wound heal-
ing and tissue regeneration. Damaged tissues mobilise and
recruit stem cells to the site of damage, where they proliferate,
differentiate, and eventually replace the damaged tissue [106].
Several studies in Drosophila [107], Xenopus [108], Planaria
[109], and Hydra [110] have indicated a facilitative role for
apoptosis as a trigger for tissue remodelling in response to tis-
sue injury, identifying caspase activation as a key requirement
for cell proliferation and stem cell recruitment. Although
counterintuitive, as apoptosis is generally considered as a
means for multicellular organisms to dispose of damaged
or unwanted cells, there is increasing evidence that dying
cells can signal their presence to the surrounding tissues
and, in doing so, elicit tissue repair and regeneration that
compensates for any loss of function caused by cell death
[111]. The first evidence of this in a mammalian model was
provided by Li et al. [36] and coined the phrase “phoenix
rising pathway,” in which tissue damage initiates tissue repair.
This study revealed that mice deficient in caspase-3 and
caspase-7, which are essential apoptotic proteases, exhibited
reduced rates of tissue repair in dorsal skin wounds and
defects in liver regeneration following partial hepatectomy.
Mechanistically, apoptotic cells released PGE
2
in a caspase-
dependent manner, and this in turn stimulates stem cell pro-
liferation and tissue regeneration [36]. Given that aberrant
apoptosis is a hallmark of cancer [4] and that activation of
caspases to induce apoptosis is the prevailing ideology of
most cancer treatments, what is the role of apoptosis-induced
compensatory proliferation in cancer development? Is the
phoenix rising pathway clinically relevant?
Cancers often acquire mutations that prevent apoptosis,
leading to the survival of precancerous cells (that would
otherwise die) and giving rise to neoplasia. This model
appears to be oversimplified, and data is emerging, which
expands and links the role of apoptosis-induced compen-
satory proliferation in normal tissue repair and regener-
ation, to tumourigenesis. Studies of 𝛾-irradiation-induced
lymphoma formation in mice deficient in PUMA, a DNA
damage induced proapoptotic mediator, showed a reduction
in apoptosis and, surprisingly, a concurrent reduction in
tumour incidence [112, 113]. Similarly, PUMA-deficient mice
treated with diethylnitrosamine, a DNA-alkylating agent
and hepatocarcinogen, showed a reduction in apoptosis of
hepatocytes and decreased tumour incidence [114]. Although
these studies lack mechanistic insight, this data indicates that
PUMA-dependent apoptotic cell death may drive compen-
satory proliferation in lymphogenesis and hepatocarcinogen-
esis. Further to this, a seminal study byHuang et al. [39] illus-
trated, in vitro and in vivo, that the phoenix rising pathway
is applicable to cancer biology, whereby apoptotic tumour
cells can stimulate the repopulation of tumours from a small
number of surviving cells, and that this process is caspase-
3-dependent and involves upregulation of arachidonic acid
and subsequent PGE
2
production (Figure 2). In this study,
labelled cancer cellswere implanted intomicewith orwithout
lethally irradiated, apoptotic, mouse embryonic fibroblast
cells (MEFs). The presence of apoptotic cells increased cell
proliferation and tumour cell growth. However implantation
of irradiated, caspase-3-deficient MEFs ablated these results.
Exogenous treatment with PGE
2
also caused cancer cells to
grow at a faster rate than untreated cells. Subsequently, Allen
et al. [115] utilised a panel of established human cancer cell
lines to show that IR-induced, caspase-3-dependent, PGE
2
production is a common response of irradiated tumour
cells and that PGE
2
production generally correlated with
enhanced growth of cells that survive irradiation and of
unirradiated cells cocultured with irradiated cells. Therefore,
the caspase-3/PGE
2
axis is a direct link between cell death and
tumour repopulation, highlighting that tumours may exploit
a tissue homeostaticmechanism to preserve themselves when
damaged by cytotoxic therapy, and given the high radiation
doses required to kill high numbers of tumour cells, the
rare surviving cells are likely to experience significant DNA
damage, and rapid proliferation of such cells may enhance
mutagenesis and drive tumour progression toward a more
metastatic state.
4. Implications for Cancer Management
and Therapy
There is accumulating evidence that the phoenix rising
pathway is clinically relevant. In patients with head and neck
cancer, high amounts of activated caspase-3 were correlated
with high rates of tumour recurrence, and in patients with
breast cancer, high caspase-3 levels were correlated with
shorter survival time [39]. This has implications for cancer
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Figure 2: Schematic representation of apoptosis-mediated tumour cell repopulation. In tumours damaged by cytotoxic therapies apoptotic
cells activate caspase-3 and caspase-7 through either intrinsic pathways, involving Apaf and caspase-9 activation, or extrinsic pathways,
involving caspase-8 activation. Activated caspase-3 and caspase-7 activate calcium-independent phospholipase A2 (iPLA
2
), which increases
the synthesis and release of arachidonic acid. Arachidonic acid is then converted into PGH
2
by COX-1 and COX-2, which is subsequently
converted into PGE
2
by the enzyme PGE
2
synthase. PGE
2
stimulated cancer stem cell proliferation and tumour repopulation (figure was
adapted from [39] with the permission of Professor Li).
therapy: efforts to develop agents that activate caspases must
be reexamined; and small molecule inhibitors of caspases
should now be evaluated for their properties to enhance
cancer chemotherapy or radiotherapy. Human clinical trials
are currently lacking in this area, but several studies using
mouse models indicate that blocking apoptosis may increase
sensitivity to radiotherapy. For example, in a mouse model
of lung cancer, treatment with a caspase-3 inhibitor led
to an increase in autophagy and radiosensitivity [116]; and
treatment with a pan-caspase inhibitor, zVAD, or small
interfering RNA directed against caspase-3 and caspase-7
led to radiosensitivity and delayed tumour growth rates,
in breast and lung xenografts [117]. In addition, a recent
study has shown that low doses of radiation cause partial
caspase-3 activation that leads to genome instability, both
in vitro and in vivo, through the generation of persistent
DNA strand breaks [118]. These findings implicate caspase-
3 as a promising target to improve chemo- and radiation-
therapy outcomes. However, inhibition of caspase-dependent
apoptosis is counterintuitive, when taking into consideration
that the aim of cytotoxic therapies is to induce apoptosis of
cancer cells, and further research is required to determine
if, in the absence of caspase-activity, cell death comes by an
alternative pathway, such as necrotic cell death or senescence.
An alternative strategy is to prevent compensatory prolif-
eration by targeting PGE
2
production, which is downstream
from caspase-3, by chemical inhibition of COX-1 and COX-
2. NSAIDS effectively target cyclooxygenase enzymes and
are widely used to treat common inflammatory diseases;
for example, naproxen and ibuprofen are widely used and
well tolerated. Selective COX-2 inhibitors, such as celecoxib,
have been marketed but many have been withdrawn due
to increased risk of myocardial infarction; however, the risk
has not been assessed for short-term courses during cancer
therapy. As we have previously discussed, overexpression of
COX-2 and chronic inflammation has been attributed to the
development of several cancer types, and there has been
extensive preclinical and epidemiological studies that support
the targeting of the COX-2 pathway for the prevention and
treatment of malignancy (reviewed extensively here [119–
121]). Several mouse studies have provided evidence of the
synergistic effect of COX-2 inhibitors in combination with
chemotherapy and radiotherapy including mouse models
of nasopharyngeal carcinoma [122], pancreatic adenocarci-
noma [123], andmedulloblastoma-derived CSCs [124]. In the
context of tumour repopulation, a seminal study by Kurtova
et al. [37] used a human bladder cancer xenograft model
to show that there is selective repopulation of the tumour
frompreviously slowly proliferating bladder tumour cells that
have markers of CSCs. This is the first study to effectively
show that CSCs actively contribute to therapeutic resistance
via the phoenix rising pathway, whereby chemotherapy effec-
tively induces apoptosis and associated PGE
2
release then
promotes neighbouring CSC repopulation, akin to how tissue
resident stem cells mobilise to wound sites during tissue
repair. Additional studies have supported that repopulation
can be abrogated by COX-2 inhibition of PGE
2
-signalling:
treatment of a panel of human cancer cell lines with the
pan COX-1 and COX-2 inhibitor, indomethacin, blocked
radiation-induced PGE
2
production, and inhibited cancer
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cell proliferation [115]; a study of prostate adenocarcinoma
mouse xenografts showed that topical application of the
NSAID, diclofenac, significantly reduced tumour growth in
combination with 3Gy irradiation [125]; and significantly,
celecoxib delivered between rounds of gemcitabine and
cisplatin substantially suppressed bladder urothelial carci-
noma xenograft regrowth and enhanced the chemothera-
peutic response in xenografts from a chemoresistant patient
[37]. These results advocate that PGE
2
-stimulated tumour
repopulation is a critical issue to consider during treatment
planning and that prospective clinical trials are needed to
define the effect of COX-2 inhibition on tumour repopulation
between cycles of chemotherapy or radiotherapy. Several
clinical studies have been conducted in which celecoxib
has been used in combination with standard chemother-
apy and radiotherapy and show varying results depending
on the type and stage of cancer [119]. A meta-analysis
of these trials showed a modest activity against advanced
cancers, but no significant effect on one-year survival rate
[126]. These studies were not in the context of blocking
apoptosis-induced compensatory proliferation to enhance
the efficacy of therapy. Future studies to address this clinical
problem are needed to define optimum treatment regimes,
the sensitivity of the CSC population to specific COX-
2 inhibitors, and to determine different pharmacokinetics
and pharmacodynamics associated with chemotherapy, as
some drugs may be better or poorer induces of tumour
repopulation. There is also a great diversity of tumours,
and it is likely that some tumour types may be more
reciprocal to apoptosis-driven tumour repopulation than
others.
NSAIDS and selective COX-2 inhibitors target not only
COX2 activity but also suppress the biosynthesis of other
physiologically important prostanoids that are associated
with the adverse effects of these drugs on cardiovascular
function including increased risk of myocardial infraction
and stroke [127]; therefore, alternative strategies to inhibit
PGE
2
production that would negate the cardiovascular risk
and lead to safer therapeutic tools are currently being investi-
gated, including selective targeting of individual prostanoids
via inhibition of their corresponding terminal synthases and
disruption of platelet-driven COX2 induction.
An attractive target for regulation of PGE
2
levels is inhi-
bition of microsomal prostaglandin E synthase-1 (mPGES-1).
mPGES-1 is the inducible terminal synthase in PGE
2
biosyn-
thesis and is functionally coupled to COX-2: the induction
of these two enzymes leads to increased PGE
2
production
[128]. In cancer, mPGES-1 is overexpressed in a number
of cancers including gastrointestinal, lung, stomach, brain,
breast, pancreas, prostate, and papillary thyroid carcinoma
[129]. Moreover, mPGES-1 expression is associated with
vascular invasion and poor prognosis in colorectal cancer
[130].The therapeutic potential of mPGES-1 has been proved
inmultiple studies usingmicemodels with genetic deletion of
mPGES-1, in which there was a decrease in the production of
PGE
2
and associated pain, fever, inflammation, and tumouri-
genesis [131–133]. Currently there are no selective mPGES-
1 inhibitors available for clinical use. However, research
is ongoing to identify and characterise specific mPGES-1
inhibitors, and we would advocate that this research should
extend to studies looking at these drugs in combination
radiotherapy and the impact on apoptosis-driven tumour cell
repopulation.
Similarly, a growing body of evidence supports the central
role of platelets in metastasis. There is extensive cross-talk
between platelets and cancer cells, whereby tumours can
stimulate platelet activation and activated platelets, in turn,
promote tumour growth and metastasis. A central event
involves an aberrant expression of COX-2 in the cancer
cells, which influences cell-cycle progression and contributes
to the acquisition of a cell migratory phenotype through
the induction of EMT gene expression profile. Platelets
are also activated in response to wound healing, and they
secrete a number of factors that are important mediators of
tissue remodelling at the site of injury. By extension, future
research should focus on the role of platelets in the tumour
microenvironment, the effect on the phoenix rising pathway
and to determine if pharmacological inhibition of platelet
function could prevent tumour repopulation and metastasis.
5. Conclusions
Recent evidence has challenged the paradigm that apoptosis
is a barrier for carcinogenesis: the common goal of standard
chemotherapy and radiotherapy is to kill cancer cells by
inducing apoptosis. However, apoptosis may be a double-
edged sword, leading initially to increased cell death of cancer
cells, but accompanied by increased PGE
2
secretion and
subsequent growth stimulation of CSCs and repopulation
of the tumour. Repopulation during chemotherapy and
radiotherapy has long been recognised as an important cause
of treatment failure. Here we have presented the phoenix
rising pathway as a potential driver of compensatory prolif-
eration, and advocated that the ability of COX-2 inhibitors
to selectively inhibit the proliferation of tumour cells during
therapy should be evaluated. Further understanding of the
biological processes of compensatory cell proliferation may
give therapeutically beneficial insight into tissue repair and
aid the development of new strategies to inhibit tumour
repopulation during therapy and improve clinical outcomes.
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